Related by context. All words. (Click for frequent words.) 74 evaluating T DM1 73 evaluating picoplatin 71 clinical trials Archexin 71 Bayer HealthCare Onyx Pharmaceuticals 71 TELINTRA R 71 pralatrexate injection folate analogue 71 assessing T DM1 70 progressive metastatic prostate 70 registrational trial 70 Prednisone Against Refractory 70 CG# oncolytic virus 70 Hsp# Inhibitor 69 Empatic ™ 69 Completes Patient Enrollment 69 IMPDH inhibitor 69 Crofelemer budesonide foam 69 Initiates Clinical Trial 69 evaluating satraplatin 69 topical antifungal product 69 Randomized Phase II 69 5 fluorouracil leucovorin 69 refractory chronic lymphocytic 69 orally inhaled migraine 68 novel orally inhaled 68 evaluating satraplatin plus 68 sapacitabine CYC# 68 dimebon latrepirdine 68 lintuzumab SGN 68 Adjuvant Treatment 68 Vascular Disrupting Agent 68 Combination REOLYSIN R 68 PI3K/Akt pathway inhibitor 68 pharmacogenomic translational research 68 VEGFR2 inhibitor 68 Initiates Phase II 68 albiglutide currently 68 personalized cellular immunotherapy 68 Pruvel TM 68 pan histone deacetylase 68 metastatic colorectal carcinoma 68 Phase 2b Clinical Trial 68 delivers fluocinolone acetonide FA 68 humanized therapeutic 67 immunotherapeutic agent 67 XL# anticancer compounds 67 PDX pralatrexate 67 PF # [002] 67 LymphoStat B belimumab 67 INSPIRE Trial Phase III 67 Telik logo TELINTRA 67 unresectable locally advanced 67 non nucleoside inhibitor 67 Phase #b/#a clinical 67 R sorafenib tablets 67 JAK2 Inhibitor 67 Meets Primary Endpoint 67 Granted Orphan Drug 67 oral picoplatin 67 metastatic pancreatic 67 Annamycin 67 Study Evaluating 67 PROVENGE ® 67 novel antimitotic agent 67 essential thrombocythemia ET 67 Hormone Refractory Prostate Cancer 67 ADVANCE ILLUMINATE 67 folinic acid FA 67 compound INCB# 67 Trial Evaluating 67 recombinant PSMA vaccine 67 ALTROPANE R 67 Presents Positive 67 phase IIb clinical 66 Metastatic Melanoma 66 CYT# potent vascular disrupting 66 AN# topical anti 66 Xcytrin R 66 AAG geldanamycin analog 66 MEND CABG II 66 elderly myelodysplastic syndromes 66 GVAX R 66 6 sulfatase 66 TNFerade ™ 66 Initiates Phase III 66 OvaRex R 66 Phase Ib II 66 alvespimycin 66 Aflibercept 66 novel tubulin binding 66 recurrent metastatic ovarian cancer 66 PANVAC VF 66 individualized cellular immunotherapy 66 Personalized Immunotherapy 66 GVAX ® 66 RANK Ligand inhibitor 66 candidate REP# 66 MKC# MT 66 Initiate Phase 66 Tramiprosate ALZHEMED TM 66 Clinical Trial Evaluating 66 Initiates Enrollment 66 RNAi Therapeutic 66 thrombin inhibiting aptamer 66 Oral Calcitonin 66 dasatinib Sprycel ® 66 Hedgehog Pathway Inhibitor 66 SUCCEED trial 66 systemic anaplastic large 66 Successfully Completes Phase 66 Romidepsin 66 imetelstat GRN#L 66 Luramist TM 66 PNP inhibitor 66 Tesetaxel 66 product candidate Lpathomab 66 targeted radiotherapeutic 66 Initiate Phase III 66 metastatic colorectal 66 candidate deforolimus 66 oncolytic virus therapies 66 ATRA IV 66 ARRY # 66 Submits Biologics License Application 65 Receives Orphan Drug Designation 65 Patients Treated With 65 Troxatyl 65 Rigel R# 65 telomerase therapeutic 65 IMiDs R 65 Synta Announces 65 Folfox 65 HER2 positive metastatic breast 65 telomerase inhibitor drug 65 selectin antagonist 65 TM pralatrexate injection 65 bavituximab monotherapy trial 65 evaluating Actimmune 65 initiated Phase Ib 65 comparing alemtuzumab 65 Initiate Clinical Trial 65 molecular imaging radiopharmaceutical 65 overactive bladder AA# 65 metaglidasen 65 novel histone deacetylase 65 RESTORE CLI trial 65 FOLOTYN ® 65 SPRYCEL ® 65 selective angiogenic kinase inhibitor 65 Antibody Drug Conjugate 65 modified glutathione analog 65 including eniluracil ADH 65 unique alkylating agent 65 Submits NDA 65 Relapsed Refractory 65 platform HDL Mimetic 65 hypoxia activated prodrug 65 Initiated Phase 65 Presents Preclinical Data 65 Completes Enrollment 65 evaluating tivozanib 65 Phase Ib IIa 65 non porcine pancreatic 65 2 methoxyestradiol 65 DG# compounds targeting 65 Investigational Oral 65 FOLFOX6 chemotherapy regimen 65 unresectable Stage III 65 cell carcinoma RCC 65 Files IND 65 Novel Oral 65 estrogen receptor beta agonist 65 ® natalizumab 65 Begins Dosing 65 accumulate preferentially 65 rALLy clinical trial 65 triggers apoptosis programmed 65 Matrix Phase 2b 65 particularly SANCTURA XR 65 CML CP 65 Demonstrates Sustained 65 5 FU leucovorin 65 Achieves Primary Endpoint 65 Phase IIb Clinical Trial 65 Panzem R 65 Archexin 65 approved incretin mimetic 65 dependent kinase inhibitor 65 virus HCV protease inhibitor 65 Ixempra 65 Multiple Ascending Dose 65 Clinical Trial Results 65 Syncria albiglutide 65 radiation enteritis 65 IMA# 65 CINQUIL 65 generation PNP inhibitor 65 candidate ridaforolimus 65 motexafin gadolinium Injection 65 candidate XP# 65 Xeloda ® 65 Cloretazine ® 65 refractory cutaneous T 65 R lenalidomide 65 Empatic TM 65 refractory colorectal cancer 65 omacetaxine mepesuccinate 64 intravesical infusion therapy 64 deCODE AF TM 64 Dose Escalation 64 Trastuzumab DM1 64 candidates Azedra TM 64 agonistic human 64 vinca alkaloid 64 ALN VSP Phase 64 anti PlGF 64 5 lipoxygenase activating 64 delivery polymer matrix 64 TOCOSOL R 64 Amigal TM 64 Testosterone MDTS R 64 data management Clintrial 64 stage IIIb IV 64 please visit www.abraxane.com 64 castration resistant hormone refractory 64 BRIM2 64 oral anti arrhythmic 64 pharmacokinetic PK study 64 stage antibody MT# 64 TO AVOID PREGNANCY WHILE 64 MT#/MEDI-# 64 novel therapeutic antibodies 64 metastatic androgen independent 64 IMiDs ® 64 Elagolix 64 lorvotuzumab mertansine 64 Acetavance TM intravenous acetaminophen 64 Phase III Clinical Trial 64 Oral Fingolimod 64 ® bortezomib 64 cancer neuroendocrine tumor 64 novel emulsion formulation 64 Biopharmaceuticals AG 64 ThermoDox R 64 Brentuximab Vedotin SGN 64 CRMD# 64 IMPACT IMmunotherapy 64 treat refractory angina 64 Recurrent Glioblastoma 64 oral prodrug 64 Zenvia ™ 64 adjuvant GIST 64 generation purine nucleoside 64 evaluating intravenous picoplatin 64 Multiple Myeloma MM 64 forodesine 64 candidate AQ4N 64 ® cetuximab 64 investigational humanized monoclonal antibody 64 AVN# Phase 64 Panzem R NCD 64 metastatic CRC 64 tumors GIST 64 systemic Phase 1b 64 Namenda Memantine HCl 64 ALN PCS 64 Ovitrelle R Serostim 64 R Saizen R 64 IMPACT DCM 64 Second Pivotal Phase 64 Initiates Clinical 64 Bosutinib 64 vaccine GMK 64 M# rationally 64 novel VDA molecule 64 hematological cancers notably 64 ELACYT 64 dextromethorphan quinidine 64 endoscopic autofluorescence imaging 64 Telik Announces 64 metastatic CRPC 64 evaluating Vectibix 64 Panzem ® 64 LymphoStat B TM 64 By JENNIFER LEARN 64 endocrine refractory 64 Demonstrates Positive 64 GetGoal Phase III 64 IgG1 monoclonal antibody 64 Syncria R 64 plus prednisone 64 read Palintologist 64 metastatic ocular 64 oral ridaforolimus 64 toenail onychomycosis 64 oral proteasome inhibitor 64 Advanced Renal Cell 64 relapsed MM 64 Phase Ib clinical trials 64 metastatic hormone refractory 64 Testosterone MDTS ® 64 markets Testim ® 63 Glufosfamide 63 Exherin 63 Deforolimus 63 cytidine nucleoside analog 63 Peginterferon alfa 2b 63 Dose Ranging Study 63 includes TOLAMBA TM 63 palifosfamide Zymafos TM 63 azilsartan medoxomil 63 signal detection CTSD 63 nilotinib Tasigna ® 63 EVIZON TM squalamine lactate 63 ZEVALIN ® 63 Kosan dependence 63 PLK1 SNALP 63 TRO# 63 Vitrasert R 63 Ozarelix 63 Tyrosine Kinase Inhibitor 63 Cloretazine R VNP#M 63 Demonstrates Significant 63 SPL# Gel vaginal microbicide 63 Alfacell proprietary ribonuclease 63 refractory indolent non 63 mitogen activated ERK kinase 63 Prodarsan R 63 oral beclomethasone dipropionate 63 histone deacetylase HDAC inhibitor 63 confirmatory pivotal 63 DNA methyltransferase inhibitors 63 human IgG1 monoclonal 63 candidate TNFerade biologic 63 orBec R oral beclomethasone 63 First Patient Enrolled 63 Randomized Phase 63 leading oral taxane 63 number NCT# ClinicalTrials.gov 63 apricitabine ATC 63 metastatic castrate resistant 63 previously untreated follicular 63 severe oral mucositis 63 monoclonal antibody IgG1 Mab 63 PRN FDA Approves 63 Commences Phase 63 Completes Patient Enrolment 63 phase IIb study 63 refractory NSCLC 63 systemic lupus erythematosus rheumatoid 63 Phase III multicenter 63 Pivotal Phase 63 HuMax TAC 63 HCV NS5B polymerase 63 trastuzumab Herceptin R 63 Ostabolin C TM 63 solid tumors ZYBRESTAT 63 Quinamed R 63 Kinase Inhibitor 63 Receives Orphan Drug 63 IIa trial 63 evaluating mipomersen 63 R#/MEM # 63 HCD# [002] 63 NPC 1C 63 SPEAR Study 63 Castration Resistant Prostate Cancer 63 lexidronam injection 63 Shows Statistically Significant 63 inflammatory PDE 63 Phase III Trial 63 Announces Poster Presentations 63 ASONEP TM 63 Investigational Treatment 63 following fluoropyrimidine oxaliplatin 63 oral Janus kinase 63 Shows Promise Against 63 dasatinib Sprycel 63 dyslipidemia hypertension diabetes 63 TKB# 63 Relapsed Multiple Myeloma 63 novel chimeric natriuretic 63 oral ghrelin agonist 63 ® lenalidomide 63 Diabetic Macular Edema DME 63 Receives Fast Track 63 Onyx Pharmaceuticals Announces 63 NOTE POSIDUR ™ 63 MKC# MKC# PP 63 Phase Ib study 63 antibody MAb 63 NASH Huntington 63 commercialize CorMedix drug 63 Advanced Melanoma 63 Presents Preclinical 63 REVIVE Diabetes 63 product platforms AZX# 63 placebo controlled dose escalation 63 FUSILEV enhances 63 induced macular edema 63 de novo kidney transplant 63 evaluating ambrisentan 63 R Bortezomib 63 Perflubutane Polymer Microspheres 63 randomized controlled Phase 63 RAS MAPK pathway 63 AKT inhibitor 63 catheter occlusion 63 limiting toxicity DLT 63 taxane chemotherapy administered 63 carcinoma mCRC 63 PEGylated Fab fragment 63 bone marrow reticulin deposition 63 Staphylococcus aureus Immune Globulin 63 orally administered inhibitor 63 SinuNase ™ 63 oral dihydropyrimidine dehydrogenase DPD 63 ThermoDox ® clinical 63 YOUR LOCAL ANIMAL SHELTER 63 receiving chemoradiation therapy 63 Novel Inhibitor 63 CCX# B 63 sapropterin dihydrochloride Phase 63 ficlatuzumab 63 DIRECT Trial 63 CHAMPION PCI 63 INTEGRILIN R eptifibatide Injection 63 next generation URAT1 63 evaluating Xcytrin 63 registrational Phase 63 omecamtiv mecarbil formerly 63 Pegloticase 62 generation Hsp# inhibitor 62 Sphingomab TM 62 Evoltra ® 62 methylnaltrexone bromide 62 HDL Selective Delipidation 62 Oral NKTR 62 MVA HPV IL2 62 relapsed refractory AML 62 OTC BB PVCT http:/www.pvct.com 62 Provectus Pharmaceuticals specializes 62 advanced carcinoid 62 Auxilium transmucosal film 62 Pivotal Phase III 62 receptor tyrosine kinase inhibitor 62 hypoxia selective 62 Omacetaxine 62 docetaxel Taxotere R 62 Immunotherapeutic 62 Files Investigational 62 undergoing elective percutaneous 62 lead molecular radiotherapeutic 62 albiglutide 62 Pivotal Study 62 recurrent metastatic 62 IL# PE#QQR 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 acetonide FA 62 pentadentate logo R 62 Prolongs Survival 62 Fx #A 62 anti VEGF aptamer 62 sunitinib Sutent 62 Pharma Merck Serono 62 seliciclib CYC# 62 induced mucositis 62 Bone Metastases 62 small molecule Hedgehog 62 NU# direct 62 class mGluR5 inhibitor 62 Phase IIb Trial 62 Drug Candidate 62 octreotide implant 62 Randomized Double blind 62 Phase 2b Trial 62 CIMZIA TM certolizumab pegol 62 Daclizumab 62 II Clinical Trial 62 targeted antifolate 62 GALNS N acetylgalactosamine 62 COLAZAL R 62 ENL recurrence 62 metastatic malignant 62 MKC# 62 OAB overactive bladder 62 CLARITY study 62 Cardioxyl Pharmaceuticals 62 cathepsin K inhibitor 62 Initiates Phase 62 ABSORB clinical 62 Capsulitis 62 Pivotal Phase II 62 Quinamed 62 brand ciclesonide HFA 62 candidate oral AP# 62 mGluR5 negative 62 AVASTIN 62 PEG SN# 62 vapreotide acetate 62 interferon beta 1a infertility 62 * olmesartan medoxomil 62 Safinamide 62 hyaluronidase enzyme 62 Polymerase Inhibitor 62 ABL inhibitor 62 cladribine Cladribine Tablets 62 IN PATIENTS WITH 62 Tarvacin Anti Cancer 62 Pivotal Trial 62 Solazed TM 62 Prospective Randomized 62 Budesonide foam crofelemer 62 EGFr humanized monoclonal antibody 62 Phase 1a clinical 62 Cutaneous T 62 bevacizumab Avastin R 62 Reports Preclinical Data 62 TRANSDUR ® 62 metastatic renal cell 62 Shows Efficacy 62 monoclonal antibody conjugated 62 Gentamicin Surgical Implant 62 Phase 1b clinical trials 62 mertansine 62 Veronate R 62 Patient Enrollment 62 adecatumumab MT# 62 plus prednisone prednisolone 62 MEK Inhibitor 62 multicenter Phase II 62 triciribine phosphate monohydrate 62 Cerebril TM 62 metastatic castration resistant 62 EMD # 62 HDAC Inhibitor 62 DIFICID ™ 62 relapsed refractory multiple myeloma 62 IMiDs ® compound 62 advanced metastatic renal 62 Spiegelmer ® 62 Temsirolimus 62 Vicriviroc 62 KRYSTEXXA TM pegloticase 62 Desvenlafaxine Succinate 62 Receives Milestone Payment 62 DepoCyt ® Abelcet ® 62 humanised monoclonal antibody 62 irinotecan cisplatin 62 R bortezomib 62 evaluating carfilzomib 62 CEL SCI Phase III 62 retinal vein occlusion induced 62 Proc Am Soc 62 Plaque Psoriasis 62 XP# XP# 62 Humanized Anti 62 Intravitreal 62 dutogliptin 62 NEBIDO VANTAS SUPPRELIN LA 62 BENLYSTA TM 62 non constipating irritable 62 bapineuzumab AAB 62 oral nucleoside analogue 62 Inc. www.micromet inc.com 62 Ceflatonin R 62 relapsed acute lymphoblastic 62 orally administered synthetic retinoid 62 include ColorectAlert TM 62 TNFerade TM 62 transthyretin mediated amyloidosis ATTR 62 FDA Accepts 62 relapsing multiple sclerosis 62 opioid naive 62 website www.celsion.com 62 investigational pharmacologically unique 62 recurrent glioblastoma multiforme 62 Panzem NCD 62 novel synthetic PEGylated 62 peptidic compound 62 Dose Ranging 62 elotuzumab 62 polysaccharide polymer 62 visit www.genenews.com 62 dose escalation clinical 62 HCV Protease Inhibitor 62 topically applied SEPA 62 anthracycline derivative 62 Diffuse Large B 62 please visit http:/www.avastin.com 62 aurora kinase 62 Submits Supplemental 62 PEG irinotecan 62 Hematide ™ 62 CTA# Injection 62 NS5b 62 Triapine 62 HepeX B TM 62 Gastrointestinal Stromal Tumors 61 anti botulism antibody 61 influenza BCX# purine nucleoside 61 Study Shows Promise 61 Topline Results 61 Cardium Therapeutics TM 61 BCG refractory carcinoma 61 dacetuzumab SGN 61 Phase 2a Trial 61 R memantine HCl 61 cetuximab Erbitux R 61 selective estrogen receptor modulator 61 ALN HPN 61 R MSCRAMM 61 Epothilone D 61 Improves Outcomes 61 MAb therapy 61 Naglazyme R 61 multiple myeloma MM 61 treat secondary hyperparathyroidism 61 PEGylated docetaxel 61 acyclovir Lauriad R 61 Fovea Pharmaceuticals subsidiary 61 LungAlert TM 61 Tumour Vascular Disrupting Agent 61 GATTEX TM 61 EOquin TM phase 61 known dihydropyrimidine dehydrogenase 61 compound CMX# 61 paclitaxel poliglumex 61 MAGE A3 ASCI 61 CDK cyclin dependent 61 candidate MyVax 61 Therapeutic Competitors Companies 61 KNS # 61 OVATURE 61 PresbyLens ® 61 Nasdaq VNDA 61 Genentech Wyeth Pharmaceuticals 61 ospemifene 61 worsening thrombocytopenia 61 Aeolus Pharmaceuticals Announces 61 Clolar ® 61 multicenter Phase 61 Submits IND 61 Hematology Molecular Pathology 61 FDA Okays 61 brain metastases originating 61 HER2 Positive 61 QNEXA ® 61 Preclinical Models 61 trastuzumab DM1 T DM1 61 PROACT Phase 2 61 Picoplatin Efficacy After 61 Efficacy Results 61 Predict Response 61 R sipuleucel T 61 AVAX AC Vaccine 61 Simulect 61 infection epistaxis dyspnea exfoliative 61 candidate brentuximab vedotin 61 occlusion PAO 61 Arzerra TM 61 ™ pralatrexate injection 61 interferon gamma 1b 61 sarcoma melanoma 61 IAP inhibitor 61 Abstract Accepted 61 Pharmacokinetics PK 61 EVIZON ™ 61 Refractory Angina 61 CYP#A# CYP#D# 61 Atypical Hemolytic Uremic Syndrome 61 Amrubicin 61 Zorbtive TM 61 apoptosis inducer 61 BRIM3 61 lymphoma multiple myeloma 61 deforolimus 61 Receives Approvable Letter 61 product TNFerade TM 61 multicenter Phase III 61 hormone LHRH antagonist 61 follicular Non Hodgkin 61 TransVax 61 Obatoclax 61 Bazedoxifene 61 Enrolls First 61 candidates Augment ™ 61 Prostate AdenoCarcinoma Treatment 61 kidney urologic 61 comparing XIENCE V 61 trial evaluating PRX# 61 fosbretabulin 61 sodium Injection 61 BioSante Pharmaceuticals Announces 61 biliary tract cancer 61 allosteric modulator NAM 61 Perforomist TM formoterol fumarate 61 IG HCR ;) CO 61 By JAMAAL ABDUL 61 SCIB1 61 ENABLE Phase 2 61 product AMD# 61 ONYX PHARMACEUTICALS 61 Genasense ® oblimersen 61 aflibercept VEGF Trap 61 Zemplar Capsules 61 Early Relapsing Multiple 61 NicVAX TM 61 ZACTIMA 61 GLP1 INT TM 61 allosteric modulator PAM 61 TRANSDUR ™ 61 inhaled liposomal ciprofloxacin 61 advanced unresectable 61 Anti Tumor Activity 61 alpha folate receptor 61 Aurora Kinase 61 Metastatic Renal Cell Carcinoma 61 CIMZIA r certolizumab pegol 61 EXPLORE Xa 61 Zalypsis 61 orBec ® oral beclomethasone 61 TBC# 61 novel L DOS# 61 Previously Treated 61 phase Ib 61 Nicotine Conjugate Vaccine 61 bucindolol hydrochloride 61 naïve HCV 61 systemic RNAi therapeutic 61 Frozen Shoulder syndrome Adhesive 61 TM Drug Eluting 61 metastatic HRPC 61 Announces Tentative Approval 61 Zenvia TM 61 Allovectin 7 61 Teva Provides Update 61 cause mesothelioma asbestosis 61 XL# XL# 61 Drug Eluting Stent System 61 relapsed multiple myeloma 61 MOVIPREP R 61 memantine HCl 61 CCR9 antagonist 61 candidate CRLX# 61 Phase 2a clinical 61 Alimentary Tract 61 CD4 monoclonal antibody 61 Cloretazine 61 SILENOR TM doxepin HCl 61 BY WILLA J. 61 TRIOLEX ™ 61 Merck OSI Pharmaceuticals 61 humanized interleukin 6 61 TLR7 agonist 61 galiximab 61 Inhalation Aerosol 61 neratinib 61 metastatic GIST 61 BRAF mutant 61 poly ADP ribose polymerase 61 Phase III PREGNANT PROCHIEVE 61 selective phosphodiesterase 61 thrombin component 61 Naive Patients 61 please visit http:/www.vandapharma.com 61 multicenter randomized placebo controlled 61 budesonide foam 61 About Positron Positron 61 include Healive TM 61 oxybutynin ATD TM 61 Receive Milestone Payment 61 inhibits dihydrofolate reductase 61 EGFR TKI 61 mitoxantrone plus 61 SoftScan R 61 Philadelphia Chromosome Positive 61 neuropathic pain spasticity 61 Tarceva TM 61 myelodysplastic myeloproliferative diseases 61 Antitumor Activity 61 metastatic carcinoma 61 PORxin TM platforms 61 Refractory Hodgkin Lymphoma 61 EDEMA3 61 resistant hormone refractory 61 PEGylated interferon beta 1a 61 Hodgkin lymphoma HL 61 Biomarker Study 61 aldehyde dehydrogenase ALDH2 deficiency 61 Phase III ADT 61 Capesaris 61 huC# DM4 61 deCODE ProstateCancer TM 61 PSMA ADC 61 Syndax Pharmaceuticals Inc. 61 markets COLAZAL 61 sirtuin inhibitor program 61 ELADUR TM 61 small molecule glucokinase 61 Dendreon investigational 61 Qnexa TM 61 indolent follicular non 60 Systemic Sclerosis 60 SUTENT ® 60 erlotinib Tarceva R 60 Amgen Neulasta R 60 include Altastaph TM 60 Completes Dosing 60 Suppository Hydrocortisone Acetate Rectal 60 Perifosine KRX 60 VELCADE melphalan 60 relapsed mantle 60 DP VPA 60 Temodar ® 60 castrate resistant prostate cancer 60 Omigard TM omiganan pentahydrochloride 60 First Patient Dosed 60 Inc. Nasdaq MITI 60 APEX PD 60 gastrointestinal stromal 60 Iluvien ® 60 autologous cellular immunotherapy 60 cosmetic cosmeceutical products 60 epilepsy neuropathic pain 60 TRX1 60 Licenses Novel 60 AVONEX ® 60 reduce serum phosphate 60 Announce License Agreement 60 RELOVAIR ™ 60 Cyclooxygenase Inhibiting Nitric Oxide 60 treatment naive genotype 60 Evaluation Program CTEP 60 GATTEX ™ 60 generation URAT1 inhibitor 60 opioid induced bowel dysfunction 60 Phase IIIb clinical 60 label Lipofen R 60 treats acute lymphoblastic 60 RhuDex TM 60 Androxal TM 60 Elotuzumab 60 Convection Enhanced Delivery 60 resectable pancreatic cancer 60 Pralatrexate 60 Drug Shows Promise 60 IMiD 60 Randomized Double Blind 60 highly purified pasteurized 60 candidate Zemiva TM 60 include Phenoptin TM 60 Telatinib 60 Phase III Pivotal 60 Peyronie disease Frozen Shoulder 60 Pertuzumab 60 docetaxel cisplatin 60 compound perifosine 60 protein tyrosine phosphatase 1B 60 novel oral anticoagulant 60 Through Glycoscience R 60 potent suppressor 60 Improves Survival 60 Solzira TM 60 developing Zerenex TM 60 Phase 2a Study 60 LHRH receptor positive 60 PKC# 60 TASKi2 60 PHASE III 60 Omnitarg 60 TELCYTA R 60 oral deforolimus 60 Node Positive 60 beta 1a 60 forodesine purine nucleoside phosphorylase 60 CD# antibody [002] 60 gastrin analogue TT 60 BR.# 60 Soft Tissue Sarcoma 60 miconazole Lauriad 60 clinical trials Archexin ® 60 Alzhemed TM 60 Colorectal Cancer CRC 60 Boehringer Ingelheim MedImmune 60 REG2 60 candidates Azedra 60 Mg Usa 60 rusalatide acetate 60 refractory metastatic 60 Canvaxin TM 60 Antigen Specific 60 docetaxel Injection Concentrate 60 OTC BB PVCT 60 coronary stent merged 60 microRNA Therapeutics 60 Phase 1b Clinical Trial 60 Ph + acute lymphoblastic 60 Tyrosine Kinase Inhibitors 60 decreased matrix metalloproteinase 60 combines Zetia 60 lung esophageal 60 Reveals Positive 60 Maximum Tolerated Dose MTD 60 vinorelbine tartrate 60 LUX Lung 60 AFREZZA TM 60 generation radiolabeled antibody 60 PINPOINT TM System 60 generation rotary VAD 60 Agonist MABA program 60 investigational mTOR inhibitor 60 Stage IIB 60 formerly LymphoStat B 60 PHX# 60 R roscovitine CDK cyclin 60 ELADUR ™ 60 demonstrated antitumor activity 60 FEMALES SHOULD BE ADVISED 60 IIb clinical trial 60 farletuzumab 60 investigational monoclonal antibody 60 Oral Laquinimod 60 VICTOR E1 60 THAT ARE DIFFICULT TO 60 Aplidin R 60 Factor Receptor 60 psoriasis inflammatory bowel 60 Cerebral Amyloid Angiopathy 60 candidate Zemiva 60 Zemiva ™ 60 TRACON Pharmaceuticals 60 personalized dendritic 60 IRX 2 60 candidate AP# 60 ALVESCO ® 60 evaluating Prochymal 60 Launches Generic Version 60 intravenous RSD# 60 Nicotine Vaccine 60 huN# DM1 60 aMCI precursor 60 Initiates Phase 2b 60 anticancer compound 60 Acute Myeloid Leukemia AML 60 inflammatory autoimmune diseases 60 COPEGUS R 60 plus dacarbazine 60 GATTEX ® 60 related CMV Retinitis 60 chemosensitizer 60 Pooled Analysis 60 Newly Diagnosed Multiple Myeloma 60 use transdermal sumatriptan 60 Single Dose 60 mGluR2 positive 60 HCV RNA polymerase 60 BiTE R 60 Dose Limiting Toxicity DLT 60 myocardial infarction ventricular fibrillation 60 Randomized Clinical Trials 60 developing adecatumumab 60 thetreatment 60 Elestrin ® 60 Phase 1b clinical 60 regorafenib 60 brentuximab vedotin SGN 60 Phase Ib Clinical Trial 60 Vidaza R 60 acute peripheral arterial 60 Therapy RecoveryRx TM 60 Chronic Lymphocytic Leukemia 60 diarrhea predominant irritable 60 somatostatin analog 60 Sirolimus eluting Coronary Stent 60 relapsed Acute Myeloid 60 Sapacitabine 60 Plicera TM 60 Phase Ib clinical 60 Severe Sepsis 60 Preclinical Study 60 MBRX 60 TM Everolimus Eluting 60 developing Bicifadine serotonin 60 refractory metastatic colorectal cancer 60 dose escalation trial 60 Submits Response 60 ALN TTR 60 R olmesartan medoxomil 60 XL# SAR# 60 Phase 2b Study 60 Renal Cell Carcinoma 60 non resectable 60 Chronic Hepatitis C 60 hormone refractory metastatic prostate 60 sorafenib tablets 60 includes Dideco CarboMedics 60 Parkinson disease psychosis 60 Troxatyl TM 60 cancer indications bafetinib